3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Early Stage Triple Negative ER Low Breast Cancer
1
Interventions
pembrolizumab
5
Radiotherapy
4
Radiation
4
ALT-803
4
fludarabine
3
Prednisone
3
Etoposide
3
Cytarabine
3
Cyclophosphamide
3
Cisplatin
3
sacituzumab govitecan
2
daratumumab
2
atezolizumab
2
Vincristine
2
Temozolomide
2
Surveys and Questionnaires
2
Specimen Handling
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Lenalidomide
2
Irinotecan
2
Gemcitabine
2
Doxorubicin
2
Blood Specimen Collection
2
Biopsy
2
Bevacizumab
2
Androgen Antagonists
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
vocimagene amiretrorepvec
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Interleukin 1 Receptor Antagonist Protein
×
90 days
×
Clear all
NCT06710197
2026-03-05
OZM-034
University Health Network, Toronto
Phase 2
Withdrawn